Demographic and desmosine data for group 2 consisting of healthy volunteers and patients with an exacerbation of chronic obstructive pulmonary disease (COPD)
| Sample type | Group 2 | |||
| Urine and sputum | Blood | |||
| Group | Healthy volunteers (HV2a) | Patients with ‘during an exacerbation’ COPD | Healthy volunteers (HV2b) | Patients with ‘during an exacerbation’ COPD |
| Number of participants | 62 | 50* | 19 | 102* |
| Gender (M/F) | 24/38 | 24/26 | 18/1 | 43/59 |
| Smoking status (smokers/e-smokers/non-smokers/unknown) | 13/41/8/0 | 31/2/15/2 | 10/0/9/0 | 55/33/0/14 |
| Age (years) | 22 (21–45) | 69 (60–74)† | 68 (65–73) | 72 (66–79) |
| Body mass index | 25±4 | 26±7 | NA | 26±7 |
| FEV1 (% predicted) | 103±13 | 39±16† | NA | 47±18 |
| uDES (ng/mg creatinine) | 8 (6–10) | 16 (14–22)† | – | – |
| bDES (ng/ml) | – | – | 0.17 (0.12–0.23) | 0.30 (0.21–0.37)† |
Data are shown as median (IQR) or mean ± SD.
Note that healthy volunteers recruited for urine and sputum analysis (HV2a) were different from those for blood analysis (HV2b).
↵* A total of 47 patients with ‘during an exacerbation’ COPD were the same as those who had urine, sputum and blood collected.
↵† p<0.001, versus healthy volunteers, Mann–Whitney test.
bDES, blood desmosine; FEV1, forced expiratory volume in 1 s; uDES, urinary desmosine.